Myrexis Reports Fiscal Year 2010 Results

Robust Oncology Pipeline Advancing

Conference Call Today at 4:30pm ET

Upcoming Events

• Announce final Phase 1 data for MPC-3100, a fully-synthetic Hsp90 inhibitor, in solid and hematological refractory cancer patients in 2H 2010
• Complete preclinical studies of cancer metabolism inhibitor (CMI) MPC-9528 and file investigational new drug application (IND) in 1H 2011
• Initiate Azixa™ Phase 2b two-arm trial in glioblastoma in 4Q 2010
• Present updated results from Azixa™ Phase 2 monotherapy trial in relapsed glioblastoma multiforme in 1H 2011

FY10 Highlights

• Completed separation from Myriad Genetics, Inc., creating independent publicly traded company; and changed name to Myrexis, Inc. from Myriad Pharmaceuticals, Inc.
• Prioritized potential first-in-class/best-in-class oncology pipeline and suspended HIV product candidates
• Presented Azixa Phase 2a data at the American Society of Clinical Oncology (ASCO) annual meeting in June 2010; durable responses in patients with glioblastoma multiforme and metastatic melanoma
• Presented preclinical results at the American Association of Cancer Research (AACR) annual meeting in April describing MPC-9528, (formerly MPI-486348) the Company's novel CMI (an inhibitor of Nicotinamide phosphoribosyltransferase, (Nampt))
• Presented interim Phase 1 data of MPC-3100 at the annual ASCO meeting in June 2010 and the AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics in November 2009
• Identified IND candidate MPI-0485520, an oral anti-interferon which targets the inhibition of a novel protein kinase, IKK epsilon, for certain cancers and chronic inflammatory diseases such as rheumatoid arthritis and lupus
• Engaged in active partnership discussions for all preclinical and clinical stage programs, including suspended HIV product candidates

SALT LAKE CITY, Sept. 9, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.

1 2 3 4 5 6 7 8 Next › Last »